|
David Brennan was appointed Chief Executive Officer of AstraZeneca effective 1 January 2006.
From 2001 until his appointment to CEO, David was President and Chief Executive Officer of AstraZeneca LP, the Company’s North America subsidiary. He was appointed Executive Board Director of AstraZeneca in 2005, with responsibility for the United States, the company's largest market, as well as all North American operations.
David began his career in 1975 at Merck, where he rose from sales representative in the U.S. Division to general manager of Chibret International, a French subsidiary of Merck specializing in ophthalmics. He joined AstraMerck in 1992 with responsibility for helping to build the joint venture into a multi-billion dollar business in the U.S. Prior to the AstraZeneca merger he was responsible for business planning and development at Astra Pharmaceuticals. He was appointed Senior Vice-President of Commercial Operations of AstraZeneca Pharmaceuticals LP in 1999. He is an alumnus of Gettysburg College.
David is an Executive Director of AstraZeneca PLC. He is a Member of the Executive Board of the Pharmaceutical Research and Manufacturers of America (PhRMA) and a Member of the Executive Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA). In addition, he is past Chairman of the Board of the Southeastern Pennsylvania Chapter of the American Heart Association, and Honorary Board member of the US CEO Roundtable on Cancer.
David is married with four children and four grandchildren. He enjoys scuba diving, cycling and is an amateur photographer. | 